RESTORE Patent Rights Act of 2024

Issues relating to legislation regarding patents; H.R. 4370/ S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (118th Congress); S. 2140 - Patent Eligibility Restoration Act (118th Congress); H.R. 9221/ S. 4840 - RESTORE Patent Rights Act of 2024 (118th Congress).

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $75,967 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent quality, Inter Partes Review, and the Patent Trial and Appeal Board (PTAB). Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370 (in the 118th Congress); Patent Eligibility Restoration Act, S. 2140 and HR 9474 (in the 118th Congress); RESTORE Patent Rights Act of 2024, S. 4840 and HR 9221 (in the 118th Congress).

Client expense: Not reported · Firm income: Not reported

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2410, Patent Eligibility Restoration Act S. 2220 & HR 4370, PREVAIL Act S. 2934, SHOP SAFE Act/HR. 8684, SHOP SAFE Act H.R. 9221 and S 4840: RESTORE Act Patents in general

Client expense: $520,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act Opposition to FTC proposal to limit non-compete agreements ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to legislation regarding patents; H.R. 4370/ S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act; S. 2140 - Patent Eligibility Restoration Act; H.R. 9221/ S. 4840 - RESTORE Patent Rights Act of 2024.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to intellectual property legislation and regulation; S. 2140, Patent Eligibility Restoration Act; S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 9221/S. 4840, RESTORE Patent Rights Act of 2024

Client expense: Not reported · Firm income: $70,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $41,265 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General discussions regarding patent-related issues, including march-in rights, WTO TRIPS waivers S. 2140/H.R. 9474 -- Patent Eligibility Restoration Act -- sections related to treatment of patent applications and their eligible status at the USPTO H.R 4370/S. 2220 -- PREVAIL Act -- related to reforms of the PTAB process at USPTO S. 4820/H.R. 9221 -- RESTORE Patent Rights Act -- related to reforms of patent law regarding injunctions against patent infringers H.R. 5475 -- Prohibiting Adversarial Patents Act -- To amend title 35, United State Code, to require the Director of the United States Patent and Trademark Office to require disclosures in patent applications regarding ties to the Peoples Republic of China and other foreign adversaries NIST Request for Information (Docket No. 230831-0207) Regarding the Draft Interagency Guidance Framework for Consideringthe Exercise of March-in Rights S. 4713 -- Inventor Diversity for Economic Advancement Act (IDEA) -- related to voluntary reporting of demographic information of patentees H.R. 8134 -- Restoring American Leadership in Innovation Act -- To promote the leadership of the United States in global innovation by establishing a robust patent system that restores and protects the right of inventors to own and enforce private property rights in inventions and discoveries, and for other purposes -- all sections

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act) Ensure free-market-based licensing terms and royalty rate settings of standard-essential patents (SEPs) Codification of 2019 Joint Policy Statement on Remedies for Standards-Essential Patents

Client expense: Not reported · Firm income: $7,600

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1707, SMART Act S. 2410, Patent Eligibility Restoration Act S. 2220 & HR 4370, PREVAIL Act S. 2934, SHOP SAFE Act/HR. 8684, SHOP SAFE Act H.R. 9221 and S 4840: RESTORE Act Patents in general

Client expense: $400,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act Opposition to FTC proposal to limit non-compete agreements ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act Opposition to FTC proposal to limit non-compete agreements ITC - IP-related issues S. 2934 - SHOP Safe Act of 2023 H.R. 8684 - Shop Safe Act Injunctive relief for patent rights holders The RESTORE Patent Rights ACT of 2024 (H.R. 9221) the IDEA Act (S.4713), the Medication Affordability and Patent Integrity Act (S.2780) Proposed Changes to Standard Essential Patent (SEPs) Policies

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to intellectual property legislation and regulation; S. 2140, Patent Eligibility Restoration Act; S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 9221/S. 4840, RESTORE Patent Rights Act of 2024

Client expense: Not reported · Firm income: $70,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent reform, Patent Trial and Appeal Board reform, assertion of patent exclusivity rights, H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840/H.R. 9221 (RESTORE Patent Rights Act), S. 2140/H.R. 9474 (Patent Eligibility Restoration Act), S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership Act), H.R. 3535 (Advancing Americas Interest Act)

Client expense: Not reported · Firm income: Not reported

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General discussions regarding patent-related issues, including march-in rights, WTO TRIPS waivers S. 2140/H.R. 9474 -- Patent Eligibility Restoration Act -- sections related to treatment of patent applications and their eligible status at the USPTO H.R 4370/S. 2220 -- PREVAIL Act -- related to reforms of the PTAB process at USPTO S. 4820/H.R. 9221 -- RESTORE Patent Rights Act -- related to reforms of patent law H.R. 5475 -- Prohibiting Adversarial Patents Act -- To amend title 35, United State Code, to require the Director of the United States Patent and Trademark Office to require disclosures in patent applications regarding ties to the Peoples Republic of China and other foreign adversaries NIST Request for Information (Docket No. 230831-0207) Regarding the Draft Interagency Guidance Framework for Consideringthe Exercise of March-in Rights S. 4713 -- Inventor Diversity for Economic Advancement Act (IDEA) -- related to voluntary reporting of demographic information of patentees Clauses in grants issued by ARPA-H regarding cost for inventions created using such funding H.R. 8134 -- Restoring American Leadership in Innovation Act -- To promote the leadership of the United States in global innovation by establishing a robust patent system that restores and protects the right of inventors to own and enforce private property rights in inventions and discoveries, and for other purposes -- all sections

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE